BR0317539A - Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais - Google Patents

Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais

Info

Publication number
BR0317539A
BR0317539A BR0317539-1A BR0317539A BR0317539A BR 0317539 A BR0317539 A BR 0317539A BR 0317539 A BR0317539 A BR 0317539A BR 0317539 A BR0317539 A BR 0317539A
Authority
BR
Brazil
Prior art keywords
inhibitors
cyclooxygenase
combination
methods
compositions
Prior art date
Application number
BR0317539-1A
Other languages
English (en)
Inventor
Timothy Maziasz
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0317539A publication Critical patent/BR0317539A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA O TRATAMENTO DE INFECçõES POR VìRUS DA HERPES USANDO INIBIDORES SELETIVOS DA OU CICLOOXIGENASE-2 OU INIBIDORES DA CICLOOXIGENASE-2 EM COMBINAçãO COM AGENTES ANTIVIRAIS". A presente invenção fornece composições e métodos para o tratamento de infecções pelo vírus do herpes. Em um aspecto, a invenção fornece uma terapia de combinação para o tratamento de uma infecção pelo vírus do herpes compreendendo a administração a um indivíduo de um agente anti-vírus do herpes em combinação com um inibidor seletivo da ciclooxigenase-2. Em um outro aspecto, a invenção fornece uma monoterapia para tratamento de uma infecção pelo vírus do herpes simples compreendendo administrar um inibidor seletivo da ciclooxigenase-2 a um indivíduo.
BR0317539-1A 2002-12-19 2003-12-19 Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais BR0317539A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43539202P 2002-12-19 2002-12-19
PCT/US2003/040615 WO2004056349A2 (en) 2002-12-19 2003-12-19 Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents

Publications (1)

Publication Number Publication Date
BR0317539A true BR0317539A (pt) 2005-11-22

Family

ID=32682230

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317539-1A BR0317539A (pt) 2002-12-19 2003-12-19 Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais

Country Status (11)

Country Link
US (1) US20040157848A1 (pt)
EP (1) EP1572186A2 (pt)
JP (1) JP2006512367A (pt)
KR (1) KR20050085724A (pt)
CN (1) CN1726018A (pt)
AU (1) AU2003297397A1 (pt)
BR (1) BR0317539A (pt)
CA (1) CA2510445A1 (pt)
MX (1) MXPA05006792A (pt)
PL (1) PL377427A1 (pt)
WO (1) WO2004056349A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061303A1 (es) * 2005-03-30 2006-12-07 Astion Dev As Composicion farmaceutica que comprende oxaprozina
US7528267B2 (en) * 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
GB201000196D0 (en) * 2010-01-07 2010-02-24 Galvez Julian M Novel combination
JP5610131B2 (ja) * 2010-03-31 2014-10-22 株式会社武蔵野免疫研究所 抗ウイルス剤
RU2452490C1 (ru) 2010-12-27 2012-06-10 Виктор Вениаминович Тец Лекарственное средство с активностью против семейства герпес-вирусов
US9642824B2 (en) * 2012-02-06 2017-05-09 Innovative Med Concepts, LLC Valaciclovir and diclofenac combination therapy for functional somatic syndromes
RU2530587C1 (ru) 2013-06-07 2014-10-10 Виктор Вениаминович Тец Способ лечения заболеваний кожи и слизистых оболочек, вызываемых вирусами простого герпеса 1-го и 2-го типов
JP2014210822A (ja) * 2014-08-19 2014-11-13 株式会社武蔵野免疫研究所 抗ウイルス剤
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
RU2605602C1 (ru) 2015-09-15 2016-12-27 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения натриевой соли (2,6-дихлорфенил)амида карбопентоксисульфаниловой кислоты
US20200253994A1 (en) * 2019-02-11 2020-08-13 Chemistryrx Pyrimidine derivative containing compositions
CN111557899B (zh) * 2020-04-30 2023-02-21 北华大学 一种治疗角膜炎的药物及其制备方法
WO2024059247A2 (en) * 2022-09-16 2024-03-21 Virios Therapeutics, Inc Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
PL195955B1 (pl) * 1996-04-12 2007-11-30 Searle & Co Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract
KR20040072720A (ko) * 2002-01-10 2004-08-18 파마시아 앤드 업존 캄파니 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 ｃｏｘ-2 억제제의 용도
WO2003065988A2 (en) * 2002-02-04 2003-08-14 Pharmacia Corporation A combination for treating cold and cough
US20030195242A1 (en) * 2002-04-15 2003-10-16 Kaufman Herbert E. Use of Cox-2 inhibitors to prevent recurrences of herpesvirus infections

Also Published As

Publication number Publication date
US20040157848A1 (en) 2004-08-12
AU2003297397A2 (en) 2005-07-07
MXPA05006792A (es) 2006-02-17
WO2004056349A3 (en) 2004-08-26
AU2003297397A1 (en) 2004-07-14
WO2004056349A2 (en) 2004-07-08
KR20050085724A (ko) 2005-08-29
JP2006512367A (ja) 2006-04-13
CA2510445A1 (en) 2004-07-08
CN1726018A (zh) 2006-01-25
EP1572186A2 (en) 2005-09-14
PL377427A1 (pl) 2006-02-06

Similar Documents

Publication Publication Date Title
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
HRP20040059B1 (en) Treatment of nail infections with no
BRPI0410846A (pt) compostos, composições e usos para o tratamento de uma infecção por flaviviridae
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
ATE381336T1 (de) Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
ATE478886T1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
EA200601591A1 (ru) Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
BRPI0407587A (pt) inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
BR0316238A (pt) Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
MXPA04006572A (es) Terapia de combinacion antivirica.
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
ATE486634T1 (de) Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0211830A (pt) Dose única de azitromicina
TR200102024T2 (tr) Yeni tedavi.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired